Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUL6GY)

Drug Name

BEMORADAN Drug Info

Synonyms

Orf-22867; RWJ-22867; Bemoradan; Rac-7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one; Rac-5-Methyl-6-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)-2,3,4,5-tetrahydropyridazin-3-one

Indication

Disease Entry	ICD 11	Status	REF
Heart failure	BD10-BD13	Phase 2	[1]

Cross-matching ID

PubChem CID: 5362399
CAS Number: CAS 112018-01-6
TTD Drug ID: DMUL6GY

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phosphodiesterase 3A (PDE3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cilostazol	DMZMSCT	Intermittent claudication	BD40.00	Approved	[3]
Aminophylline	DML2NIB	Bronchial asthma	CA23	Approved	[4]
Anagrelide	DMSQ8MD	Thrombocythemia	3B63	Approved	[5]
Enoximone	DMQVZJD	Congestive heart failure	BD10	Approved	[6]
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[7]
CI-930	DMADPQX	N. A.	N. A.	Discontinued in Phase 2	[8]
EMD-53998	DMVS8IE	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 1	[2]
IMAZODAN	DMWTFO3	N. A.	N. A.	Terminated	[9]
LAS-31180	DMW2K1L	Heart failure	BD10-BD13	Terminated	[10]
BMY-20844	DMDPJ8M	N. A.	N. A.	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 3A (PDE3A)	TT06AWU	PDE3A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Evaluation of the excretion, and metabolism of the cardiotonic agent bemoradan in male rats and female beagle dogs. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):263-71.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
4	Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
5	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
6	Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
7	Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
8	Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
9	3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
10	Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
11	Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.